Search

Your search keyword '"Shabto, Julie M."' showing total 44 results
Start Over Author "Shabto, Julie M."
44 results on '"Shabto, Julie M."'

3. Intraosseous venous malformation of the frontal bone with extension into the frontal sinus and orbit.

Author

Shabto, Julie M., Coombs, Allison, Stevens, Shanlee, Adapa, Arjun, Overdevest, Jonathan B., Youngerman, Brett, and Kazim, Michael

Subjects
*FRONTAL bone, *FRONTAL sinus, *LITERATURE reviews, *CAVERNOUS sinus, EYE-socket tumors
Abstract

We present a novel case of intraosseous venous malformation of the frontal bone with dehiscence of the inner table of the frontal calvarium and extension into the frontal sinus and orbit. This case report discusses the surgical management of this intraosseous lesion achieved with a multidisciplinary approach involving otolaryngology and neurosurgical teams. We also present a review of the literature of the pathophysiology of venous malformations, the imaging modalities that aid in diagnosis of these lesions and the management options. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

6. Pediatric-Type Follicular Lymphoma of the Conjunctiva in Two Adolescents.

Author

Shabto, Julie M., Gru, Alejandro A., Soderquist, Craig R., Yip, James, Chadburn, Amy, Gu, Yue, Marr, Brian, Yeager, Lauren, and Dagi Glass, Lora R.

Subjects
FOLLICULAR lymphoma, BLACK children, TEENAGERS, CONJUNCTIVA, GERMINAL centers, THYROID cancer
Abstract

The authors present two cases of conjunctival pediatric-type follicular lymphoma. A 14-year-old Black boy and 14-year-old Black girl were each referred for evaluation of a painless salmon-colored conjunctival lesion. Both patients underwent excisional biopsy. Histopathology demonstrated follicles with germinal centers composed of atypical B-cells with high Ki67 proliferation index, positive staining for CD20, CD10, and BCL6, and negative for BCL2. This series contributes two cases to the limited literature and presents the first case reported in a female. [J Pediatr Ophthalmol Strabismus. 2024;61(4):e33–e38.] [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

8. Clinical outcomes of advanced stage cancer patients treated with sequential immunotherapy in phase 1 clinical trials

Author

Martini, Dylan J., Liu, Yuan, Shabto, Julie M., Lewis, Colleen, Kline, Meredith R., Collins, Hannah, Akce, Mehmet, Kissick, Haydn T., Carthon, Bradley C., Shaib, Walid L., Alese, Olatunji B., Pillai, Rathi N., Steuer, Conor E., Wu, Christina S., Lawson, David H., Kudchadkar, Ragini R., Master, Viraj A., El-Rayes, Bassel F., Ramalingam, Suresh S., Owonikoko, Taofeek K., Harvey, R. Donald, and Bilen, Mehmet Asim

Published
2019
Full Text
View/download PDF

9. Immune-Related Adverse Events and Clinical Outcomes in Advanced Urothelial Cancer Patients Treated With Immune Checkpoint Inhibitors

Author

Sanda, Gregory E, primary, Shabto, Julie M, additional, Goyal, Subir, additional, Liu, Yuan, additional, Martini, Dylan J, additional, Nazha, Bassel, additional, Brown, Jacqueline T, additional, Yantorni, Lauren B, additional, Russler, Greta Anne, additional, Caulfield, Sarah, additional, Joshi, Shreyas S, additional, Narayan, Vikram M, additional, Kissick, Haydn, additional, Ogan, Kenneth, additional, Master, Viraj A, additional, Carthon, Bradley C, additional, Kucuk, Omer, additional, and Bilen, Mehmet Asim, additional

Published
2023
Full Text
View/download PDF

11. Spontaneous rupture of secondary iris inclusion cyst causing acute glaucoma and other ocular sequelae

Author

Shabto, Julie M., Price, Kenneth W., Allen, John C., Craven, Caroline, Jones, Jeremy K., and Wells, Jill

Subjects
Case Report, General Medicine
Abstract

A 63-year-old woman with a known secondary iris inclusion cyst in her right eye presented with headache, blurry vision, and eye pain of 3 days’ duration. Initial findings were notable for significant decrease in vision and elevated intraocular pressure in the right eye, with diffuse microcystic corneal edema, diffuse anterior chamber flare with minimal cellular reaction, and a significantly decompressed iris inclusion cyst. On gonioscopy, the right eye was open to scleral spur, and no pigment was visualized. Patient history and presentation were consistent with a diagnosis of spontaneous rupture of iris inclusion cyst causing secondary glaucoma. Iris inclusion cysts are not uncommon; however, ocular outcomes are generally benign and limited to obstruction of the pupillary axis.

Published
2022

12. Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy

Author

Bilen, Mehmet Asim, Shabto, Julie M., Martini, Dylan J., Liu, Yuan, Lewis, Colleen, Collins, Hannah, Akce, Mehmet, Kissick, Haydn, Carthon, Bradley C., Shaib, Walid L., Alese, Olatunji B., Steuer, Conor E., Wu, Christina, Lawson, David H., Kudchadkar, Ragini, Master, Viraj A., El-Rayes, Bassel, Ramalingam, Suresh S., Owonikoko, Taofeek K., and Harvey, R. Donald

Published
2019
Full Text
View/download PDF

16. Clinical outcomes in advanced urothelial cancer (UC) patients who experienced immune-related adverse events (irAEs) after immune checkpoint inhibitor monotherapy (ICI).

Author

Sanda, Gregory E., primary, Shabto, Julie M., additional, Goyal, Subir, additional, Liu, Yuan, additional, Martini, Dylan J., additional, Nazha, Bassel, additional, Brown, Jacqueline T, additional, Yantorni, Lauren Beth, additional, Russler, Greta, additional, Caulfield, Sarah, additional, Joshi, Shreyas S., additional, Narayan, Vikram M., additional, Kissick, Haydn, additional, Ogan, Kenneth, additional, Master, Viraj A., additional, Carthon, Bradley Curtis, additional, Kucuk, Omer, additional, and Bilen, Mehmet Asim, additional

Published
2022
Full Text
View/download PDF

17. Body Composition as an Independent Predictive and Prognostic Biomarker in Advanced Urothelial Carcinoma Patients Treated with Immune Checkpoint Inhibitors

Author

Martini, Dylan J., primary, Shabto, Julie M., additional, Goyal, Subir, additional, Liu, Yuan, additional, Olsen, T. Anders, additional, Evans, Sean T., additional, Magod, Benjamin L., additional, Ravindranathan, Deepak, additional, Brown, Jacqueline T., additional, Yantorni, Lauren, additional, Russler, Greta Anne, additional, Caulfield, Sarah, additional, Goldman, Jamie M., additional, Nazha, Bassel, additional, Joshi, Shreyas Subhash, additional, Kissick, Haydn T., additional, Ogan, Kenneth E., additional, Harris, Wayne B., additional, Kucuk, Omer, additional, Carthon, Bradley C., additional, Master, Viraj A., additional, and Bilen, Mehmet Asim, additional

Published
2021
Full Text
View/download PDF

18. Modified Glasgow Prognostic Score associated with survival in metastatic renal cell carcinoma treated with immune checkpoint inhibitors

Author

Brown, Jacqueline T, primary, Liu, Yuan, additional, Shabto, Julie M, additional, Martini, Dylan, additional, Ravindranathan, Deepak, additional, Hitron, Emilie Elise, additional, Russler, Greta Anne, additional, Caulfield, Sarah, additional, Yantorni, Lauren, additional, Joshi, Shreyas Subhash, additional, Kissick, Haydn, additional, Ogan, Kenneth, additional, Nazha, Bassel, additional, Carthon, Bradley C, additional, Kucuk, Omer, additional, Harris, Wayne B, additional, Master, Viraj A, additional, and Bilen, Mehmet Asim, additional

Published
2021
Full Text
View/download PDF

19. Baseline modified Glasgow prognostic score (mGPS) in patients with metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICI).

Author

Brown, Jacqueline T, primary, Liu, Yuan, additional, Martini, Dylan J., additional, Shabto, Julie M., additional, Russler, Greta, additional, Caulfield, Sarah, additional, Yantorni, Lauren Beth, additional, Joshi, Shreyas S., additional, Kissick, Haydn, additional, Ogan, Kenneth, additional, Nazha, Bassel, additional, Carthon, Bradley Curtis, additional, Kucuk, Omer, additional, Harris, Wayne, additional, Master, Viraj A., additional, and Bilen, Mehmet Asim, additional

Published
2021
Full Text
View/download PDF

20. Baseline Modified Glasgow Prognostic Score Associated with Survival in Metastatic Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors

Author

Brown, Jacqueline T., primary, Liu, Yuan, additional, Shabto, Julie M., additional, Martini, Dylan J., additional, Ravindranathan, Deepak, additional, Hitron, Emilie Elise, additional, Russler, Greta Anne, additional, Caulfield, Sarah, additional, Yantorni, Lauren Beth, additional, Joshi, Shreyas S., additional, Kissick, Haydn, additional, Ogan, Kenneth, additional, Harris, Wayne B., additional, Carthon, Bradley C., additional, Kucuk, Omer, additional, Master, Viraj A., additional, and Bilen, Mehmet Asim, additional

Published
2021
Full Text
View/download PDF

22. Novel risk group stratification for metastatic urothelial cancer patients treated with immune checkpoint inhibitors

Author

Shabto, Julie M., primary, Martini, Dylan J., additional, Liu, Yuan, additional, Ravindranathan, Deepak, additional, Brown, Jacqueline, additional, Hitron, Emilie E., additional, Russler, Greta A., additional, Caulfield, Sarah, additional, Kissick, Haydn, additional, Alemozaffar, Mehrdad, additional, Ogan, Kenneth, additional, Harris, Wayne B., additional, Master, Viraj A., additional, Kucuk, Omer, additional, Carthon, Bradley C., additional, and Bilen, Mehmet A., additional

Published
2020
Full Text
View/download PDF

23. Association of baseline modified Glasgow Prognostic Score (mGPS) with survival outcomes in patients with metastatic urothelial cell carcinoma (mUCC) treated with immune checkpoint inhibitors (CPI).

Author

Brown, Jacqueline T, primary, Liu, Yuan, additional, Shabto, Julie M., additional, Martini, Dylan J., additional, Ravindranathan, Deepak, additional, Hitron, Elise, additional, Russler, Greta, additional, Caulfield, Sarah, additional, Yantorni, Lauren Beth, additional, Joshi, Shreyas S., additional, Kissick, Haydn, additional, Ogan, Kenneth, additional, Harris, Wayne, additional, Carthon, Bradley Curtis, additional, Kucuk, Omer, additional, Master, Viraj A., additional, and Bilen, Mehmet Asim, additional

Published
2020
Full Text
View/download PDF

24. Novel risk scoring system for metastatic renal cell carcinoma (mRCC) patients (pts) treated with cabozantinib (C).

Author

Kline, Meredith R, primary, Martini, Dylan J., additional, Liu, Yuan, additional, Shabto, Julie M., additional, Carthon, Bradley Curtis, additional, Hitron, Elise, additional, Russler, Greta, additional, Caulfield, Sarah, additional, Yantorni, Lauren Beth, additional, Harris, Wayne, additional, Kucuk, Omer, additional, Master, Viraj A., additional, and Bilen, Mehmet Asim, additional

Published
2020
Full Text
View/download PDF

25. Association of modified Glasgow Prognostic Score (mGPS) with survival outcomes in patients with metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (CPI).

Author

Brown, Jacqueline T, primary, Liu, Yuan, additional, Martini, Dylan J., additional, Shabto, Julie M., additional, Hitron, Elise, additional, Russler, Greta, additional, Caulfield, Sarah, additional, Yantorni, Lauren Beth, additional, Joshi, Shreyas S., additional, Kissick, Haydn, additional, Ogan, Kenneth, additional, Carthon, Bradley Curtis, additional, Kucuk, Omer, additional, Harris, Wayne, additional, Master, Viraj A., additional, and Bilen, Mehmet Asim, additional

Published
2020
Full Text
View/download PDF

26. Combined Effect of Sarcopenia and Systemic Inflammation on Survival in Patients with Advanced Stage Cancer Treated with Immunotherapy

Author

Bilen, Mehmet Asim, primary, Martini, Dylan J., additional, Liu, Yuan, additional, Shabto, Julie M., additional, Brown, Jacqueline T., additional, Williams, Milton, additional, Khan, Amir I., additional, Speak, Alexandra, additional, Lewis, Colleen, additional, Collins, Hannah, additional, Kissick, Haydn T., additional, Carthon, Bradley C., additional, Akce, Mehmet, additional, Shaib, Walid L., additional, Alese, Olatunji B., additional, Pillai, Rathi N., additional, Steuer, Conor E., additional, Wu, Christina S., additional, Lawson, David H., additional, Kudchadkar, Ragini R., additional, El-Rayes, Bassel F., additional, Ramalingam, Suresh S., additional, Owonikoko, Taofeek K., additional, Harvey, R. Donald, additional, and Master, Viraj A., additional

Published
2019
Full Text
View/download PDF

27. Novel Risk Scoring System for Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors

Author

Martini, Dylan J., primary, Liu, Yuan, additional, Shabto, Julie M., additional, Carthon, Bradley C., additional, Hitron, Emilie Elise, additional, Russler, Greta Anne, additional, Caulfield, Sarah, additional, Kissick, Haydn T., additional, Harris, Wayne B., additional, Kucuk, Omer, additional, Master, Viraj A., additional, and Bilen, Mehmet Asim, additional

Published
2019
Full Text
View/download PDF

28. Adiposity may predict survival in patients with advanced stage cancer treated with immunotherapy in phase 1 clinical trials

Author

Martini, Dylan J., primary, Kline, Meredith R., additional, Liu, Yuan, additional, Shabto, Julie M., additional, Williams, Milton A., additional, Khan, Amir Ishaq, additional, Lewis, Colleen, additional, Collins, Hannah, additional, Akce, Mehmet, additional, Kissick, Haydn T., additional, Carthon, Bradley C., additional, Shaib, Walid L., additional, Alese, Olatunji B., additional, Pillai, Rathi N., additional, Steuer, Conor E., additional, Wu, Christina S., additional, Lawson, David H., additional, Kudchadkar, Ragini R., additional, El‐Rayes, Bassel F., additional, Ramalingam, Suresh S., additional, Owonikoko, Taofeek K., additional, Harvey, R. Donald, additional, Master, Viraj A., additional, and Bilen, Mehmet Asim, additional

Published
2019
Full Text
View/download PDF

29. Novel risk stratification criteria of metastatic renal cell carcinoma (mRCC) patients (pts) treated with immune checkpoint inhibitors (ICI).

Author

Martini, Dylan J, primary, Liu, Yuan, additional, Shabto, Julie M., additional, Carthon, Bradley Curtis, additional, Russler, Greta, additional, Hitron, Elise, additional, Caulfield, Sarah, additional, Kissick, Haydn, additional, Harris, Wayne, additional, Kucuk, Omer, additional, Master, Viraj A., additional, and Bilen, Mehmet Asim, additional

Published
2019
Full Text
View/download PDF

30. Inflammatory markers at baseline (C1) and cycle 3 (C3) and their association with clinical outcomes in urothelial cancer patients (pts) treated with immunotherapy (IO).

Author

Shabto, Julie M., primary, Martini, Dylan J, additional, Liu, Yuan, additional, Ravindranathan, Deepak, additional, Kline, Meredith R, additional, Hitron, Elise, additional, Russler, Greta, additional, Caulfield, Sarah, additional, Kissick, Haydn, additional, Alemozaffar, Mehrdad, additional, Ogan, Kenneth, additional, Harris, Wayne, additional, Kucuk, Omer, additional, Carthon, Bradley Curtis, additional, Master, Viraj A., additional, and Bilen, Mehmet Asim, additional

Published
2019
Full Text
View/download PDF

31. Sites of metastasis (mets) and association with clinical outcomes (CO) in metastatic renal cell carcinoma (mRCC) patients (pts) treated with cabozantinib (cabo).

Author

Martini, Dylan J, primary, Shabto, Julie M., additional, Liu, Yuan, additional, Carthon, Bradley Curtis, additional, Speak, Alexandra, additional, Hitron, Elise, additional, Russler, Greta, additional, Caulfield, Sarah, additional, Ogan, Kenneth, additional, Harris, Wayne, additional, Master, Viraj A., additional, Kucuk, Omer, additional, and Bilen, Mehmet Asim, additional

Published
2019
Full Text
View/download PDF

32. Body mass index (BMI) and toxicities and association with clinical outcomes (CO) in metastatic renal cell carcinoma (mRCC) patients (pts) treated with cabozantinib (cabo).

Author

Martini, Dylan J, primary, Shabto, Julie M., additional, Liu, Yuan, additional, Carthon, Bradley Curtis, additional, Speak, Alexandra, additional, Hitron, Elise, additional, Russler, Greta, additional, Caulfield, Sarah, additional, Ogan, Kenneth, additional, Harris, Wayne, additional, Master, Viraj A., additional, Kucuk, Omer, additional, and Bilen, Mehmet Asim, additional

Published
2019
Full Text
View/download PDF

33. Association of inflammation and clinical outcomes (CO) in metastatic renal cell carcinoma (mRCC) patients (pts) treated with cabozantinib (cabo).

Author

Martini, Dylan J, primary, Shabto, Julie M., additional, Liu, Yuan, additional, Carthon, Bradley Curtis, additional, Speak, Alexandra, additional, Hitron, Elise, additional, Russler, Greta, additional, Caulfield, Sarah, additional, Ogan, Kenneth, additional, Harris, Wayne, additional, Kucuk, Omer, additional, Master, Viraj A., additional, and Bilen, Mehmet Asim, additional

Published
2019
Full Text
View/download PDF

34. Sites of metastases (mets) and their association with clinical outcomes (CO) in urothelial cancer patients (pts) treated with immunotherapy (IO).

Author

Shabto, Julie M., primary, Martini, Dylan J, additional, Liu, Yuan, additional, Ravindranathan, Deepak, additional, Kline, Meredith R, additional, Hitron, Elise, additional, Russler, Greta, additional, Caulfield, Sarah, additional, Kissick, Haydn, additional, Alemozaffar, Mehrdad, additional, Ogan, Kenneth, additional, Harris, Wayne, additional, Master, Viraj A., additional, Kucuk, Omer, additional, Carthon, Bradley Curtis, additional, and Bilen, Mehmet Asim, additional

Published
2019
Full Text
View/download PDF

35. Association between immune-related adverse events (irAEs) and clinical outcomes (CO) in advanced urothelial cancer patients (pts) treated with immunotherapy (IO).

Author

Shabto, Julie M., primary, Martini, Dylan J, additional, Liu, Yuan, additional, Ravindranathan, Deepak, additional, Kline, Meredith R, additional, Hitron, Elise, additional, Russler, Greta, additional, Caulfield, Sarah, additional, Kissick, Haydn, additional, Alemozaffar, Mehrdad, additional, Ogan, Kenneth, additional, Harris, Wayne, additional, Master, Viraj A., additional, Carthon, Bradley Curtis, additional, Kucuk, Omer, additional, and Bilen, Mehmet Asim, additional

Published
2019
Full Text
View/download PDF

36. Analysis of toxicity and clinical outcomes (CO) in full versus reduced dose cabozantinib (cabo) in metastatic renal cell carcinoma (mRCC) patients (pts).

Author

Martini, Dylan J, primary, Shabto, Julie M., additional, Liu, Yuan, additional, Carthon, Bradley Curtis, additional, Speak, Alexandra, additional, Hitron, Elise, additional, Russler, Greta, additional, Caulfield, Sarah, additional, Ogan, Kenneth, additional, Harris, Wayne, additional, Master, Viraj A., additional, Kucuk, Omer, additional, and Bilen, Mehmet Asim, additional

Published
2019
Full Text
View/download PDF

37. Combined Effect of Sarcopenia and Systemic Inflammation on Survival in Patients with Advanced Stage Cancer Treated with Immunotherapy.

Author

Bilen, Mehmet Asim, Martini, Dylan J., Liu, Yuan, Shabto, Julie M., Brown, Jacqueline T., Williams, Milton, Khan, Amir I., Speak, Alexandra, Lewis, Colleen, Collins, Hannah, Kissick, Haydn T., Carthon, Bradley C., Akce, Mehmet, Shaib, Walid L., Alese, Olatunji B., Pillai, Rathi N., Steuer, Conor E., Wu, Christina S., Lawson, David H., and Kudchadkar, Ragini R.

Subjects
SKELETAL muscle physiology, BIOMARKERS, COMPARATIVE studies, COMPUTED tomography, CONFIDENCE intervals, IMMUNOTHERAPY, INFLAMMATION, LYMPHOCYTES, MELANOMA, MONOCYTES, NEUTROPHILS, RISK management in business, SURVIVAL, TUMORS, GASTROINTESTINAL tumors, COMORBIDITY, TREATMENT effectiveness, SARCOPENIA, PROPORTIONAL hazards models, RETROSPECTIVE studies, PLATELET count, SYSTEMIC inflammatory response syndrome
Abstract

Background: Sarcopenia and inflammation have been associated with poor survival in patients with cancer. We explored the combined effects of these variables on survival in patients with cancer treated with immunotherapy. Methods: We performed a retrospective review of 90 patients enrolled on immunotherapy‐based phase I clinical trials at Emory University from 2009 to 2017. Baseline neutrophil‐to‐lymphocyte ratio, monocyte‐to‐lymphocyte ratio, and platelet‐to‐lymphocyte ratio (PLR) were used as surrogates of inflammation. The skeletal muscle index (SMI) was derived from the skeletal muscle density calculated from baseline abdominal computed tomography images. Optimal cutoffs for continuous inflammation biomarkers and SMI were determined by bias‐adjusted log‐rank test. A four‐level risk stratification was used to create low‐risk (PLR <242 and nonsarcopenic), intermediate‐risk (PLR <242 and sarcopenic), high‐risk (PLR ≥242 and nonsarcopenic), and very‐high‐risk (PLR ≥242 and sarcopenic) groups with subsequent association with survival. Results: Most patients (59%) were male, and the most common cancers were melanoma (33%) and gastrointestinal (22%). Very high‐risk, high‐risk, and intermediate‐risk patients had significantly shorter overall survival (hazard ratio [HR], 8.46; 95% confidence interval [CI], 2.65–27.01; p <.001; HR, 5.32; CI, 1.96–14.43; p =.001; and HR, 4.01; CI, 1.66–9.68; p =.002, respectively) and progression‐free survival (HR, 12.29; CI, 5.15–29.32; p <.001; HR, 3.51; CI, 1.37–9.02; p =.009; and HR, 2.14; CI, 1.12–4.10; p =.022, respectively) compared with low‐risk patients. Conclusion: Baseline sarcopenia and elevated inflammatory biomarkers may have a combined effect on decreasing survival in immunotherapy‐treated patients in phase I trials. These data may be immediately applicable for medical oncologists for the risk stratification of patients beginning immunotherapeutic agents. Implications for Practice: Sarcopenia and inflammation have been associated with poor survival in patients with cancer, but it is unclear how to apply this information to patient care. The authors created a risk‐stratification system that combined sarcopenia and platelet‐to‐lymphocyte ratio as a marker of systemic inflammation. The presence of sarcopenia and systemic inflammation decreased progression‐free survival and overall survival in our cohort of 90 patients who received immunotherapy in phase I clinical trials. The data presented in this study may be immediately applicable for medical oncologists as a way to risk‐stratify patients who are beginning treatment with immunotherapy. The interaction between chronic inflammation and body composition is particularly important in the era of immunotherapy, considering that immune checkpoint inhibitors rely on the host immune system for their efficacy. This article reports on the combined effects of inflammation and sarcopenia on clinical outcomes in patients with solid tumors treated with immunotherapy‐based regimens. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

38. Novel Risk Scoring System for Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors.

Author

Martini, Dylan J., Liu, Yuan, Shabto, Julie M., Carthon, Bradley C., Hitron, Emilie Elise, Russler, Greta Anne, Caulfield, Sarah, Kissick, Haydn T., Harris, Wayne B., Kucuk, Omer, Master, Viraj A., and Bilen, Mehmet Asim

Subjects
ANTINEOPLASTIC agents, RISK of metastasis, BIOMARKERS, CANCER patients, CONFIDENCE intervals, IMMUNOTHERAPY, METASTASIS, MULTIVARIATE analysis, RENAL cell carcinoma, RISK assessment, SURVIVAL, BODY mass index, PROPORTIONAL hazards models, RETROSPECTIVE studies, DESCRIPTIVE statistics, KAPLAN-Meier estimator, PROGRAMMED cell death 1 receptors
Abstract

Background: The International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) criteria are the gold standard for risk‐stratifying patients with metastatic renal cell cancer (mRCC). We developed a novel risk scoring system for patients with mRCC treated with immune checkpoint inhibitors (ICIs). Methods: We performed a retrospective analysis of 100 ICI‐treated patients with mRCC at Winship Cancer Institute from 2015 to 2018. Several baseline variables were collected, including markers of inflammation, body mass index (BMI), and sites of metastatic disease, and all were considered for inclusion in our risk scoring system. Upon variable selection in multivariable model, monocyte‐to‐lymphocyte ratio (MLR), BMI, and number and sites of metastases at baseline were used for risk score calculation. Patients were categorized using four‐level risk groups as good (risk score = 0), intermediate (risk score = 1), poor (risk score = 2), or very poor (risk score = 3–4). Cox's proportional hazard model and the Kaplan‐Meier method were implemented for survival outcomes. Results: Most patients were male (66%) with clear cell renal cell carcinoma (72%). The majority (71%) received anti–programmed cell death protein‐1 monotherapy. Our risk scoring criteria had higher Uno's concordance statistics than IMDC in predicting overall survival (OS; 0.71 vs. 0.57) and progression‐free survival (0.61 vs. 0.58). Setting good risk (MLR <0.93, BMI ≥24, and D_Met = 0) as the reference, the OS hazard ratios were 29.5 (95% confidence interval [CI], 3.64–238.9), 6.58 (95% CI, 0.84–51.68), and 3.75 (95% CI, 0.49–28.57) for very poor, poor, and intermediate risk groups, respectively. Conclusion: Risk scoring using MLR, BMI, and number and sites of metastases may be an effective way to predict survival in patients with mRCC receiving ICI. These results should be validated in a larger, prospective study. Implications for Practice: A risk scoring system was created for patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors. The results of this study have significant implications for practicing oncologists in the community and academic setting. Importantly, these results identify readily available risk factors that can be used clinically to risk‐stratify patients with metastatic renal cell carcinoma who are treated with immune checkpoint inhibitors. Considering the increasing number of treatment options for patients with metastatic renal cell carcinoma, it is becoming more important to identify factors that increase the likelihood of responses to systemic therapy. This article describes a novel risk scoring system for patients with metastatic renal cell carcinoma treated with ICI, focusing on risk from systemic inflammation, number and sites of metastatic disease, and body composition. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

39. Adiposity may predict survival in patients with advanced stage cancer treated with immunotherapy in phase 1 clinical trials.

Author

Martini, Dylan J., Kline, Meredith R., Liu, Yuan, Shabto, Julie M., Williams, Milton A., Khan, Amir Ishaq, Lewis, Colleen, Collins, Hannah, Akce, Mehmet, Kissick, Haydn T., Carthon, Bradley C., Shaib, Walid L., Alese, Olatunji B., Pillai, Rathi N., Steuer, Conor E., Wu, Christina S., Lawson, David H., Kudchadkar, Ragini R., El‐Rayes, Bassel F., and Ramalingam, Suresh S.

Subjects
TUMOR classification, CLINICAL trials, PROPORTIONAL hazards models, IMMUNOTHERAPY, BODY mass index
Abstract

Background: Body mass index (BMI) is used to define obesity, but it is an imperfect measure of body composition. In the current study, the authors explored the association between types of fat and survival in patients treated with immunotherapy.Methods: A retrospective analysis of 90 patients who were treated with immunotherapy on phase 1 clinical trials at the Winship Cancer Institute in Atlanta, Georgia, from 2009 through 2017 was performed. Overall survival (OS) and progression-free survival (PFS) were used to measure clinical outcomes. Baseline BMI and radiographic images at the middle of the third lumbar vertebrae were obtained. Fat densities were calculated and converted to indices (subcutaneous fat index [SFI], intermuscular fat index [IFI], and visceral fat index [VFI]) after dividing by height in meters squared. Risk groups were created using recursive partitioning and the regression trees method for SFI and IFI, which were selected by stepwise variable selection among all fat-related variables. The Cox proportional hazards model and Kaplan-Meier method were used for the association with OS and PFS.Results: The majority of patients (59%) were male and diagnosed with melanoma (33%) or gastrointestinal cancers (22%). The median BMI was 27.4 kg/m2 , the median SFI was 62.78, the median IFI was 4.06, and the median VFI was 40.53. Low-risk patients (those with an SFI ≥73) had a significantly longer OS (hazard ratio, 0.20; 95% CI, 0.09-0.46 [P < .001]) and PFS (hazard ratio, 0.38; 95% CI, 0.20-0.72 [P = .003]) compared with patients at intermediate risk (those with an SFI <73 and IFI <3.4) and poor risk (those with an SFI <73 and IFI ≥3.4). The Uno concordance statistics were found to be higher for fat risk groups than BMI in predicting OS (0.603 vs 0.574; P = .581) and PFS (0.602 vs 0.586; P = .71).Conclusions: Increased BMI, increased SFI, and decreased IFI may be associated with prolonged survival in patients with cancer who are treated with immunotherapy. Further studies are needed to elucidate the effect of adiposity on the host immune response to immunotherapy. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

40. The prognostic and predictive impact of inflammatory biomarkers in patients who have advanced-stage cancer treated with immunotherapy

Author

Bilen, Mehmet A., primary, Martini, Dylan J., additional, Liu, Yuan, additional, Lewis, Colleen, additional, Collins, Hannah H., additional, Shabto, Julie M., additional, Akce, Mehmet, additional, Kissick, Haydn T., additional, Carthon, Bradley C., additional, Shaib, Walid L., additional, Alese, Olatunji B., additional, Pillai, Rathi N., additional, Steuer, Conor E., additional, Wu, Christina S., additional, Lawson, David H., additional, Kudchadkar, Ragini R., additional, El-Rayes, Bassel F., additional, Master, Viraj A., additional, Ramalingam, Suresh S., additional, Owonikoko, Taofeek K., additional, and Harvey, R. Donald, additional

Published
2018
Full Text
View/download PDF

41. Early change in blood-based biomarkers and association with clinical outcome (CO) in advanced stage cancer patients (pts) treated with immunotherapy (IO).

Author

Martini, Dylan J., primary, Liu, Yuan, additional, Lewis, Colleen Margaret, additional, Shabto, Julie M., additional, Akce, Mehmet, additional, Kissick, Haydn, additional, Carthon, Bradley Curtis, additional, Shaib, Walid Labib, additional, Alese, Olatunji B., additional, Pillai, Rathi Narayana, additional, Steuer, Conor Ernst, additional, Wu, Christina, additional, Lawson, David H., additional, Kudchadkar, Ragini Reiney, additional, El-Rayes, Bassel F., additional, Master, Viraj A., additional, Ramalingam, Suresh S., additional, Owonikoko, Taofeek Kunle, additional, Harvey, R. Donald, additional, and Bilen, Mehmet Asim, additional

Published
2018
Full Text
View/download PDF

42. The prognostic and predictive impact of inflammatory biomarkers in patients who have advanced-stage cancer treated with immunotherapy.

Author

Bilen, Mehmet A., Martini, Dylan J., Liu, Yuan, Lewis, Colleen, Collins, Hannah H., Shabto, Julie M., Akce, Mehmet, Kissick, Haydn T., Carthon, Bradley C., Shaib, Walid L., Alese, Olatunji B., Pillai, Rathi N., Steuer, Conor E., Wu, Christina S., Lawson, David H., Kudchadkar, Ragini R., El‐Rayes, Bassel F., Master, Viraj A., Ramalingam, Suresh S., and Owonikoko, Taofeek K.

Subjects
CANCER risk factors, CANCER treatment, IMMUNOTHERAPY, BIOLOGICAL tags, TUMORS, COMPARATIVE studies, RESEARCH methodology, MEDICAL cooperation, PROGNOSIS, RESEARCH, SURVIVAL analysis (Biometry), TUMOR classification, LOGISTIC regression analysis, EVALUATION research, TREATMENT effectiveness, RETROSPECTIVE studies, LEUKOCYTE count, LYMPHOCYTE count, PLATELET count
Abstract

Background: Optimal prognostic and predictive biomarkers for patients with advanced-stage cancer patients who received immunotherapy (IO) are lacking. Inflammatory markers, such as the neutrophil-to-lymphocyte ratio (NLR), the monocyte-to-lymphocyte ratio (MLR), and the platelet-to-lymphocyte ratio (PLR), are readily available. The authors investigated the association between these markers and clinical outcomes of patients with advanced-stage cancer who received IO.Methods: A retrospective review was conducted of 90 patients with advanced cancer who received treatment on phase 1 clinical trials of IO-based treatment regimens. NLR, MLR, and PLR values were log-transformed and treated as continuous variables for each patient. Overall survival (OS), progression-free survival (PFS), and clinical benefit were used to measure clinical outcomes. For univariate associations and multivariable analyses, Cox proportional-hazards models or logistic regression models were used.Results: The median patient age was 63 years, and most were men (59%). The most common histologies were melanoma (33%) and gastrointestinal cancers (22%). High baseline NLR, MLR, and PLR values were associated significantly with worse OS and PFS (P < .05) and a lower chance of benefit (NLR and PLR; P < .05). Increased NLR, MLR, and PLR values 6 weeks after baseline were associated with shorter OS and PFS (P ≤ .052).Conclusions: Baseline and early changes in NLR, MLR, and PLR values were strongly associated with clinical outcomes in patients who received IO-based treatment regimens on phase 1 trials. Confirmation in a homogenous patient population treated on late-stage trials or outside of trial settings is warranted. These values may warrant consideration for inclusion when risk stratifying patients enrolled onto phase 1 clinical trials of IO agents. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

44. Analysis of Toxicity and Clinical Outcomes in Full Versus Reduced Starting Dose Cabozantinib in Metastatic Renal Cell Carcinoma Patients

Author

Martini, Dylan J., Evans, Sean T., Liu, Yuan, Shabto, Julie M., Uner, Ogul E., Olsen, T. Anders, Brown, Jacqueline T., Russler, Greta Anne, Yantorni, Lauren, Caulfield, Sarah, Goldman, Jamie M., Nazha, Bassel, Harris, Wayne B., Master, Viraj A., Kucuk, Omer, Carthon, Bradley C., and Bilen, Mehmet Asim

Abstract

Full dose cabozantinib for metastatic renal cell carcinoma (mRCC) is 60 mg, but adverse events (AEs) may require dose reductions. Limited data exist comparing efficacy among cabozantinib doses. We compared AEs and clinical outcomes in mRCC patients treated with full vs. reduced starting cabozantinib dose.

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results